Notice Number: NOT-AG-23-039
Request for Information (RFI) on the need for research studies to evaluate potential effects of types of blood pressure reducing agents on the development of mild cognitive impairment and dementia
Response Date: December 31, 2023
NIA and NHLBI request input on the need for research studies to evaluate potential effects of types of blood pressure reducing agents on the development of mild cognitive impairment and dementia.
There have been recommendations in the literature (e.g., van Dalen JW et al., 2021; D’Silva EA et al., 2022; Marcum ZA et al., 2022; Marcum ZA et al., 2023) for additional research on the hypothesis that, compared to anti-hypertensive drugs that inhibit type 2 and 4 angiotensin II receptors, anti-hypertensive drugs that stimulate type 2 and 4 angiotensin II receptors reduce the incidence of mild cognitive impairment and/or dementia in older adults with hypertension. This hypothesis could be further explored in observational studies using causal interferences methods, randomized trials primarily focused on psychometric outcomes, or phase 3 trials on mild cognitive impairment and/or dementia.
This Request for Information (RFI) solicits comments and suggestions on the aforementioned approaches, their combinations, or novel ideas that are most appropriate at this stage of our scientific knowledge. NIA and NHLBI seek input from all interested stakeholders, including researchers, clinicians, academic institutions, medical institutions, professional organizations or societies, as well as other interested members of the public. Organizations are strongly encouraged to submit a single response that reflects the view of their organization and membership as a whole. A synopsis of your preferred option or options would be welcomed.
For more information, please see the announcement website.